Quest Diagnostics stock after-hours at EUR 207.45, last at Lang & Schwarz on October 2, 2026
Published on 10/05/2026 at 23:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Quest Diagnostics stock was last at EUR 207.45 at Lang & Schwarz on October 2, 2026.
Trading reference
Lang & Schwarz’s previous close was the latest available reference for the after-hours publication. The next price is shown from the start of trading by the continuously updated real-time quote of Quest Diagnostics stock.
Haystack MRD study reports clinical findings
A study published in The Journal of Molecular Diagnostics reported on October 1, 2026, that Quest Diagnostics’ Haystack MRD test showed 100% specificity, with no false-positive results, at both three- and five-year follow-up in the evaluated cohort. Sensitivity was 100% at three-year follow-up and 83.3% at five-year follow-up. The study also validated the test’s analytical performance across 23 solid tumor types, according to an issuer-provided release distributed by PR Newswire.
Third-quarter results scheduled
Quest Diagnostics Incorporated said in a September 22, 2026, release that it plans to report third-quarter 2026 financial results before the U.S. market opens on October 22. The company said its conference call will begin at 8:30 a.m. Eastern Time, with the earnings release and webcast posted on its investor website, according to PR Newswire.
